Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 10/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.81 |
| ▸ | TSHR | P16473 | 5/20 | 0.81 |
| ▸ | TP53 | P04637 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | S100B | P04271 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL310203 | 0.90 | CYP3A4 (0.90) | CYP3A4TDP1ALDH1A1TSHRTP53 | |
| SCHEMBL29764072 | 0.90 | CYP3A4 (0.90) | CYP3A4TDP1ALDH1A1TSHRTP53 | |
| Orthotolidine SCHEMBL49414 | 0.90 | CYP3A4 (1.00) | CYP3A4TDP1ALDH1A1TSHRTP53 | |
| Orthotolidine SCHEMBL29386552 | 0.90 | CYP3A4 (1.00) | CYP3A4TDP1ALDH1A1TSHRTP53 | |
| Orthotolidine SCHEMBL29365329 | 0.90 | CYP3A4 (1.00) | CYP3A4TDP1ALDH1A1TSHRTP53 | |
| Orthotolidine SCHEMBL11189493 | 0.87 | CYP3A4 (0.94) | CYP3A4TDP1ALDH1A1TSHRTP53 | |
| Orthotolidine SCHEMBL20547383 | 0.87 | CYP3A4 (0.94) | CYP3A4TDP1ALDH1A1TSHRTP53 | |
| Orthotolidine SCHEMBL22129692 | 0.87 | CYP3A4 (0.94) | CYP3A4TDP1ALDH1A1TSHRTP53 | |
| Orthotolidine SCHEMBL6009632 | 0.87 | CYP3A4 (0.94) | CYP3A4TDP1ALDH1A1TSHRTP53 | |
| Orthotolidine SCHEMBL867121 | 0.87 | CYP3A4 (0.94) | CYP3A4TDP1ALDH1A1TSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119258129-A | Extract for treating psoriasis and preparation method and application thereof | 中国中医科学院广安门医院 | 2025-01-07 | — | — | CN | disclosed |
| CN-117929728-A | Immunomagnetic bead detection kit for pig transmissible gastroenteritis virus IgG antibody and application thereof | 河南农业大学 | 2024-04-26 | — | — | CN | disclosed |
| US-20240016921-A1 | ANTIGEN SPECIFIC IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE | VAKSTON, INC. | 2024-01-18 | — | — | US | disclosed |
| EP-4248983-A2 | ANTIGEN SPECIFIC IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE | Akston Biosciences Corporation (US) | 2023-09-27 | — | — | EP | disclosed |
| US-11707517-B2 | Antigen specific immunotherapy for COVID-19 fusion proteins and methods of use | AKSTON BIOSCIENCES CORPORATION (US) | 2023-07-25 | — | — | US | disclosed |
| EP-3972987-B1 | ANTIGEN SPECIFIC IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE | AKSTON BIOSCIENCES CORP (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3972987-A1 | ANTIGEN SPECIFIC IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE | Akston Biosciences Corporation (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20220088182-A1 | ANTIGEN SPECIFIC IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE | VAKSTON, INC. | 2022-03-24 | — | — | US | disclosed |
| WO-2021207599-A9 | ANTIGEN SPECIFIC IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE | AKSTON BIOSCIENCES CORPORATION (US) | 2022-01-06 | — | — | WO | disclosed |
| US-11213581-B2 | Antigen specific immunotherapy for COVID-19 fusion proteins and methods of use | AKSTON BIOSCIENCES CORPORATION (US) | 2022-01-04 | — | — | US | disclosed |
| US-20170071200-A1 | SELF INDICATING ANTIMICROBIAL CHEMISTRY | ECOLAB USA INC. | 2017-03-16 | — | — | US | disclosed |
| EP-2623987-B1 | Solid phase multi-analyte assay | PSYCHEMEDICS CORP (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-2623987-A1 | Solid phase multi-analyte assay | Psychemedics Corporation (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-2281204-A1 | SOLID PHASE MULTI-ANALYTE ASSAY | Psychemedics Corporation (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20100279941-A1 | CD36 MODULATION AND USES THEREOF | VALORISATION-RECHERCHE, LIMITED PARTNERSHIP (CA) | 2010-11-04 | — | — | US | disclosed |
| WO-2009134855-A1 | SOLID PHASE MULTI-ANALYTE ASSAY | PSYCHEMEDICS CORPORATION (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20050026826-A1 | Feline proinsulin, insulin and constituent peptides | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., THE | 2005-02-03 | — | — | US | disclosed |
| EP-0407172-B1 | Aromatic polyimide separation membrane | MITSUBISHI CHEM IND (JP) | 1994-02-23 | — | — | EP | disclosed |
| US-5112941-A | A fluorinated membranes with high selectivity | MITSUBISHI KASEI CORPORATION (JP) | 1992-05-12 | — | — | US | disclosed |
| EP-0407172-A1 | Aromatic polyimide separation membrane | MITSUBISHI KASEI CORPORATION (JP) | 1991-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279941-A1 | CD36 MODULATION AND USES THEREOF | FABP3, TNNI3, SCARB1 | CYP3A4 4500/4885TDP1 4093/4885ALDH1A1 1464/4885 |
| US-20170071200-A1 | SELF INDICATING ANTIMICROBIAL CHEMISTRY | HPD, HAO2, OAT | CYP3A4 427/4885TDP1 1985/4885ALDH1A1 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.